Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of LY2127399 versus placebo in adults with rheumatoid arthritis
2010-022206-40Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tabalumab in rheumatoid arthritis (RA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: ACR20 response rate over 24 weeks, Superiority of LY2127399 120 mg every 4 weeks versus placebo and 1 more. Started Nov 2010; status: completed.
02
Drugs
tabalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-022206-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022206-40.